Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Jazz Pharmaceuticals (JAZZ) stocks in Canada

Learn how to easily invest in Jazz Pharmaceuticals stocks.

Jazz Pharmaceuticals is a biotechnology business based in the US. Jazz Pharmaceuticals stocks (JAZZ.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $183.34 – a decrease of 2.05% over the previous week. Jazz Pharmaceuticals employs 1,940 staff and has a trailing 12-month revenue of around $2.9 billion.

How to buy shares in Jazz Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – JAZZ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Jazz Pharmaceuticals stock price (NASDAQ:JAZZ)

Use our graph to track the performance of JAZZ stocks over time.

Jazz Pharmaceuticals shares at a glance

Information last updated 2022-01-17.
Latest market close$140.64
52-week range$117.64 - $189.00
50-day moving average $130.18
200-day moving average $151.08
Wall St. target price$201.35
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.76

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Jazz Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Jazz Pharmaceuticals price performance over time

Historical closes compared with the close of $140.64 from 2022-01-19

1 week (2022-01-13) -2.05%
1 month (2021-12-20) 11.18%
3 months (2021-10-20) -3.45%
6 months (2021-07-20) -19.78%
1 year (2021-01-20) -15.93%
2 years (2020-01-17) -6.89%
3 years (2019-01-18) 8.96%
5 years (2017-01-20) 13.53%

Is Jazz Pharmaceuticals under- or over-valued?

Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jazz Pharmaceuticals's PEG ratio

Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.9772. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Jazz Pharmaceuticals's EBITDA

Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.

The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Jazz Pharmaceuticals financials

Revenue TTM $2.9 billion
Operating margin TTM 23.41%
Gross profit TTM $2.2 billion
Return on assets TTM 4.46%
Return on equity TTM -4.4%
Profit margin -5.62%
Book value $64.17
Market capitalisation $8.9 billion

TTM: trailing 12 months

Jazz Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Jazz Pharmaceuticals's total ESG risk score

Total ESG risk: 31.66

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Jazz Pharmaceuticals's environmental score

Environmental score: 4.18/100

Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Jazz Pharmaceuticals's social score

Social score: 24.74/100

Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Jazz Pharmaceuticals's governance score

Governance score: 13.74/100

Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Jazz Pharmaceuticals's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.

Jazz Pharmaceuticals share dividends

We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.

Jazz Pharmaceuticals share price volatility

Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $117.64 up to $189. A popular way to gauge a stock's volatility is its "beta".

JAZZ.US volatility(beta: 0.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.9412. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. ; Codiak BioSciences, Inc. ; Pfenex, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site